Datos del Documento

Por favor, use este identificador para citar o enlazar este documento: https://ria.asturias.es/RIA/handle/123456789/10947
Título : Ig-like transcript 2 (ILT2) blockade and lenalidomide restore NK cell function in Chronic Lymphocytic Leukemia
Autor : Villa, Mónica
Sordo-Bahamonde, Christian
Lorenzo-Herrero, Seila
Gonzalez-Rodríguez, Ana Pilar
Rodríguez-Payer, Ángel
González-García, Esther
López-Soto, Alejandro
González, Segundo
Palabras clave : chronic lymphocytic leukemia
NK cells
Fecha de publicación : 11-dic-2018
Editorial : Anahid Jewett, University of California
Citación : Villa-Álvarez M, Sordo-Bahamonde C, Lorenzo-Herrero S, Gonzalez-Rodriguez AP, Payer AR, Gonzalez-Garcia E, Villa-Álvarez MC, López-Soto A and Gonzalez S (2018) Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia. Front. Immunol. 9:2917. doi: 10.3389/fimmu.2018.02917
Resumen : One of the cardinal features of chronic lymphocytic leukemia (CLL) is its association with a profound immunosuppression. NK cell function is markedly impaired in CLL patients, who show a significant dysregulation of the expression of activating and inhibitory receptors. Here, we analyzed the role of the novel inhibitory receptor Ig-like transcript 2 (ILT2, also termed LIR-1, LILRB1) in the regulation of NK cells in CLL. Our results show that ILT2 expression was significantly decreased on leukemic cells and increased on NK cells of CLL patients, particularly in those with advanced disease and with bad prognostic features, such as those carrying chromosome del(11q). The immunomodulatory drug lenalidomide may regulate the expression of ILT2 and its ligands in CLL since it significantly increased the expression of ILT2 and partially reestablished the expression of its ligands on leukemic cells. Furthermore, lenalidomide significantly increased the activation and proliferation of NK cells, which was strongly enhanced by ILT2 blockade. Combining ILT2 blockade and lenalidomide activated NK cell cytotoxicity resulting in increased elimination of leukemic cells from CLL patients. Overall, we describe herein the role of an inhibitory receptor involved in the suppression of NK cell activity in CLL, which is restored by ILT2 blockade in combination with lenalidomide, suggesting that it may be an interesting therapeutic strategy to be explored in this disease.
URI : https://ria.asturias.es/RIA/handle/123456789/10947
ISSN : 1664-3224
Aparece en las colecciones: Open Access DRIVERset

Archivos en este documento:
Fichero Tamaño Formato  
Archivo.pdf1.94 MBAdobe PDFVer/Abrir
Mostrar el registro Completo

Ver estadísticas del documento

Este documento está sujeto a una licencia Creative Commons: Licencia Creative Commons Creative Commons